Table 3. Polymorphisms in selected candidate genes and melanoma risk.
| SNP | Wild type | Heterozygous/variant carriers | Homozygous variant | p | ||
|---|---|---|---|---|---|---|
| case/control | case/control | OR(95% CI) | case/control | OR(95% CI) | ||
| IL-4 | ||||||
| rs2243248 | 180/185 | 31/27 | 1.27 (0.69, 2.36) | 0.45 | ||
| rs2070874 | 160/165 | 52/43 | 1.16 (0.69, 1.94) | 5/6 | 1.12 (0.28, 4.48) | 0.85 |
| IL-4R | ||||||
| rs1805010 | 67/57 | 104/110 | 0.80 (0.48, 1.33) | 43/50 | 0.71 (0.38, 1.32) | 0.52 |
| rs1801275 | 120/121 | 64/65 | 1.10 (0.68, 1.80) | 11/7 | 1.70 (0.58, 4.96) | 0.61 |
| IL-6 | ||||||
| rs2069827 | 149/156 | 48/38 | 1.40 (0.81, 2.41) | 0.22 | ||
| rs1800797 | 68/71 | 102/100 | 1.08 (0.66, 1.75) | 28/34 | 0.89 (0.45, 1.75) | 0.84 |
| rs1800795 | 69/69 | 106/102 | 1.05 (0.65, 1.70) | 32/33 | 0.93 (0.48, 1.81) | 0.93 |
| rs1554606 | 60/55 | 102/92 | 0.98 (0.58, 1.64) | 40/44 | 0.78 (0.41, 1.46) | 0.69 |
| rs2069849 | 202/200 | 9/13 | 0.76 (0.28, 2.04) | 0.58 | ||
| rs2069861 | 169/162 | 39/43 | 0.89 (0.52, 1.54) | 0.68 | ||
| rs1818879 | 100/91 | 79/85 | 0.92 (0.57, 1.47) | 25/23 | 1.18 (0.58, 2.40) | 0.79 |
| IL-6R | ||||||
| rs4845617 | 75/74 | 110/116 | 0.74 (0.46, 1.19) | 28/20 | 0.98 (0.46, 2.05) | 0.40 |
| rs12083537 | 125/135 | 74/66 | 1.04 (0.66, 1.65) | 16/8 | 2.16 (0.82, 5.69) | 0.30 |
| rs4075015 | 78/70 | 108/104 | 1.22 (0.75, 1.97) | 27/36 | 0.89 (0.45, 1.77) | 0.55 |
| rs6684439 | 64/80 | 125/97 | 1.74 (1.07, 2.81) | 28/33 | 0.93 (0.47, 1.83) | 0.035 |
| rs4845618 | 58/66 | 121/93 | 1.72 (1.04, 2.84) | 31/42 | 1.03 (0.53, 1.98) | 0.06 |
| rs4845622 | 62/78 | 119/97 | 1.69 (1.03, 2.75) | 28/34 | 0.98 (0.50, 1.93) | 0.06 |
| rs8192284 | 63/81 | 118/97 | 1.68 (1.04, 2.73) | 30/35 | 1.01 (0.52, 1.95) | 0.06 |
| rs4329505 | 153/146 | 62/65 | 0.82 (0.51, 1.31) | 0.40 | ||
| rs4240872 | 96/79 | 58/56 | 0.81 (0.47, 1.39) | 0.44 | ||
| rs2229238 | 153/139 | 64/73 | 0.86 (0.55, 1.35) | 0.51 | ||
| IL-10 | ||||||
| rs1800890 | 87/72 | 96/111 | 0.74 (0.47, 1.19) | 29/26 | 0.92 (0.47, 1.82) | 0.45 |
| rs1800896 | 57/64 | 112/103 | 1.25 (0.76, 2.07) | 46/44 | 1.13 (0.61, 2.09) | 0.68 |
| rs1800871 | 115/114 | 84/83 | 0.99 (0.63, 1.56) | 11/7 | 1.43 (0.50, 4.09) | 0.79 |
| rs1800872 | 121/124 | 83/80 | 1.05 (0.67, 1.65) | 9/9 | 0.98 (0.35, 2.77) | 0.97 |
Unconditional logistic regression adjusted for the matching variables (age and race [Caucasian and missing]), constitutional susceptibility score, family history of melanoma, the number of lifetime severe sunburns that blistered, sunlamp use or tanning salon attendance (yes/no), cumulative sun exposure while wearing a bathing suit, and geographic region.
We estimated the odds ratios (OR) of heterozygous and homozygous variant groups separately with the wild type as the reference and the p values were obtained from 2-degree of freedom (df) tests. For some SNPs with expected cell count in homozygous variant group of fewer than 5 for either cases or controls, we combined heterozygote and homozygous variant into one category (variant carriers), and the p values are based on 1- df tests.
The number of participants does not sum to total women because of missing data on genotype.